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Metabolic Syndrome
Armindo Miguel de Jesus Sousa de Araújo Ribeiro
Abstract
Metabolic syndrome (MS) is recognized by a set of cardiovascular risk factors 
(CVRF) that usually coincide with insulin resistance and hyperglycemia. These risk 
factors include hyperglycemia (fasting glucose > 100 mg/dl), high blood pressure 
(SAD ≥ 130 mmHg and TAD ≥ 85 mmHg), triglyceride increase (≥150 mg/dl), 
decreased HDL levels <40 mg/dl, and central obesity (waist circumference ≥102 cm 
in men and ≥88 cm in women). The purpose of this chapter is to review the natural 
history of metabolic syndrome and epidemiology and to review risk factors for the 
appearance of metabolic syndrome, pathophysiology, and biochemistry among 
the various cardiovascular risk factors and their importance within the metabolic 
syndrome.
Keywords: diabetes, hypertension, dyslipidemia
1. Introduction
The purpose of this chapter is to provide a review of the pathophysiology of 
metabolic syndrome (MS) and the relationship between its different components. 
Because this is a very broad subject, not all aspects will be discussed. Throughout 
the chapter, a bibliographic reference is left for each topic so that this can be looked 
into more deeply. This is a non-systematic review of the literature through research 
on PubMed and Google.
At an epidemiologic study conducted by Armindo Sousa Ribeiro et al, in 
a Portuguese population, was found that 23.8% of the population has MS 
more prevalent in 24 males, no smoking, no significant alcohol consumption, 
sedentary life style, with a high body mass index (BMI) and its prevalence 
increases with age [1]. Each CVRF has different importance in the metabolic 
syndrome [2].
In Western societies, cardiovascular diseases (CVD) are the main cause of mor-
tality and morbidity for both sexes. This fact entails very high social and economic 
costs [3].
CVDs are the biggest cause of mortality worldwide. In the 2010 Global Burden 
of Disease Study, CVD is estimated to cause 15.6 million deaths per year worldwide, 
corresponding to 29.6% of all deaths [4]. Although the tendency is to reduce the 
number of deaths in Europe due to CVD, this remains the main cause of death, cor-
responding to more than 4 million deaths per year, that is to say 45% of all deaths 
recorded in Europe [4]. Of the CVD, coronary heart disease remains the most 
important cause of death in both genders, which corresponds to 19% in the male sex 
and 20% in the female sex.
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2. Metabolic syndrome and cardiovascular risk factors (CVRF)
2.1 Definition
There are several definitions of MS. MS groups a constellation of pathophysi-
ological factors that increase the risk of developing diabetes mellitus (DM) type 2 
and CVD [5–10]. At present, attempts have been made to unify criteria to have a 
consensus on its diagnosis [11].
The World Health Organization (WHO), International Diabetes Federation 
(IDF), National Cholesterol Education Program Adult Treatment Panel III 
Figure 1. 
Components of the metabolic syndrome considering its definition: according to the National Cholesterol 
Education Program Adult Treatment Panel III (ATP III), World Health Organization (WHO), 
American Association of Clinical Endocrinologists (AACE), and International Diabetes Federation 
(IDF).
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(NCEP-ATP III), and the American Association of Clinical Endocrinologists (AACE) 
have proposed their diagnostic criteria or components of MS (Figure 1) [11].
In 2009, representatives of the IDF and the American Heart Association/National 
Heart, Lung, and Blood Institute (AHA/NHLBI)-ATP III Guidelines discussed 
resolving differences between definitions of MS, unifying criteria [6, 11]. The 
definition of MS according to the unification of criteria (harmonizing the metabolic 
syndrome) is used for many international works and publications and requires the 
presence of three of the following five criteria:
1. Elevation of fasting blood glucose (≥100 mg/dl) or receiving antidiabetic 
treatment with insulin or oral antidiabetics
2. Elevation of systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood 
pressure (PAD) ≥ 85 mmHg or receiving antihypertensive drug treatment
3. High-density lipoprotein (HDL) cholesterol values <40 mg/dl (men) 
or <50 mg/dl (women)
4. Triglycerides ≥150 mg/dl or under treatment with specific lipid lowering 
agents
5. Abdominal perimeter ≥102 cm (men) or ≥88 cm (women) [6, 12]
The concept of MS was carried out in a progressive manner. Its clinical impor-
tance is enormous due to the fact that it can identify patients with high risk of 
suffering some CVD and/or DM, allowing a preventive intervention [6, 13, 14].
The notion that CVRF has a tendency to aggregation allows an earlier diagnosis 
of MS, thus also leading to the early introduction of therapeutic, pharmacological, 
or non-pharmacological measures.
2.2 Historical evolution
The interest in the MS is not something recent. Its nomenclature has evolved 
over the years.
About 260 years ago, before the description of MS, the Italian anatomist and 
doctor, Morgagni, identified the association between visceral obesity, arterial 
hypertension (AHT), atherosclerosis, hyperuricemia, and frequent episodes of 
sleep apnea. In the mid-twentieth century, French physicist Vague first identified 
the relationship between android obesity and the increased prevalence of DM 
and CVD. In the 1960s Avogaro and Crepaldi attributed the name “plurimetabolic 
syndrome” to the simultaneous presence of obesity, AHT, and DM. They verified 
that all these abnormalities were frequent among the population and contributed to 
an increase in cardiovascular risk [15]. A decade later, Haller related this set of risk 
factors with atherosclerosis [15].
In 1980, Vague suggested that adipose tissue alone had little effect on the onset 
of DM in obese individuals. It is currently known that central or android obesity is a 
predisposing factor for DM and atherosclerosis and affects insulin secretion unlike 
gynoid obesity [15].
In 1988, Reaven described this phenomenon as syndrome X, the set of hypergly-
cemia and insulin resistance, obesity, dyslipidemia, and hypertension. Reaven also 
suggested that insulin resistance and the consequent increase in blood insulin levels 
were the central pathophysiological features in syndrome X which in itself was a 
risk factor for CVD [15, 16].
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In 1991, Ferrannini and his colleagues referred to this as insulin resistance 
syndrome [15, 17].
In 1993, Van Gaal attributed for the first time the name MS to all comorbidities 
associated with visceral obesity and currently this nomenclature is being used [15].
The concept of MS has evolved significantly in the last decade, which resulted 
in the presentation of multiple clinical definitions by different scientific societies. 
In general terms as it was widely treated, MS is defined as an aggregation of sev-
eral CVRF in the same individual. The nuclear elements for the classification and 
diagnosis of MS are basically obesity, abnormal glycemic metabolism, iatrogenic 
dyslipidemia, and hypertension.
The metabolic syndrome was defined by the World Health Organization (WHO) 
in 1998 [13, 15]. In 2001, there was a new revision of the definition through the 
National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP 
III), where glycemia is not considered an essential factor; in this way it only 
becomes one of the diagnostic components of MS [18].
With the verification of evidence of the relationship between central obesity 
and cardiovascular risk, there was a tendency to value this diagnostic component 
for MS more. Thus, in 2004, the International Diabetes Federation (IDF) created a 
new definition of MS, where central obesity, defined by the value of the abdominal 
circumference, would be essential for diagnosis [7, 19]. With the adoption of this 
definition, an increase in the prevalence of MS was observed in a large part of the 
populations studied, particularly in the elderly [20].
In 2005, a new review of the criteria by the American Heart Association/
National Heart, Lung, and Blood Institute (AHA/NHLBI) maintained the criteria 
of the NCEP-ATP III [21]. The justification was the fact that in that criterion a single 
etiology for MS does not stand out and is of simpler application. They modified 
only the cutoff point of fasting blood glucose from 110 to 100 mg/dl, an adjust-
ment promoted by the American Diabetes Association (ADA) in the diagnosis of 
DM. However, the first Brazilian Guideline for the Diagnosis of Treatment of MS, 
of 2005, uses the criteria of the NCEP-ATP III, of 2001, for diagnosis [22, 23]. In 
the criteria of the IDF, the component of the abdominal circumference becomes 
essential, using a smaller waist circumference, and categorized more people as 
having the MS than the ATP III definition. However, higher values of abdominal 
circumference in older people have been related to lower values of body mass index 
(BMI), in relation to younger adults [24–28].
2.3 Prevalence of metabolic syndrome
The prevalence of MS varies according to geographic area, with age, race, sex, 
and classification used for diagnosis [29].
The DARIOS study performs a pooled analysis of 11 studies in 24,670 Spanish 
individuals aged 35–74, using the criteria of the IDF/NHLBI/AHA-2009, and shows 
a prevalence of 32% in men and 29% in women [12, 30].
The West of Scotland Coronary Prevention Study (WOSCOPS), one of the larg-
est in Europe, reports a general prevalence of 26.2% [31]
The Third National Health and Nutrition Examination Survey (NHANES III) 
, in the USA showed that 7% of individuals between the ages of 20 and 29, 42% of 
individuals with ages between 60 and 69 years, and 44% of individuals with ages 
over 70 years presented MS. The overall prevalence was 23.7% in the 8814 adults 
who entered the study. This study showed that the incidence increased with age, 
mainly after 40 years, with significant variations consistent with ethnicity, being 
the most frequent MS in Hispanics (31.9%) compared with Caucasians (23.8%) 
and African-Americans (21.6%). A similar prevalence was recorded in both sexes, 
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although it was more prevalent in males in Caucasians and in females in African-
Americans and Hispanics [32].
Based on the Diabetes Epidemiology Collaborative Analysis of Diagnostic 
Criteria in Europe (DECODE) study of Europe in 2004, the prevalence of MS was 
15.7% in male and 14.2% in the female [33]. Epidemiological studies on MS have 
suggested that the prevalence of MS in Western societies is high and is increasing 
due to the increase in obesity, especially in younger individuals [34].
In Portugal there are few studies on the prevalence of MS. In 2004, an epidemio-
logical study was carried out in Porto where the prevalence of MS was 23.9%, being 
more prevalent in females (27%) than in males (19.1%) [35].
In 2008, the first study was conducted on the prevalence of MS and its cardio-
vascular complications in the Portuguese adult population at the primary care level 
in continental Portugal, Azores, and Madeira—VALSIM study (epidemiological 
study of the prevalence of metabolic syndrome in the Portuguese population). In 
this study, 719 family doctors participated. The study was carried out between April 
2006 and November 2007. A total of 16,856 individuals were evaluated between 
the ages of 18 and 96, with averages of 58.1 ± 15.1 years. This study showed a high 
prevalence of MS in adults affecting 27.5% of the population analyzed, being more 
prevalent in females (28.7%) compared with males (26%). This study revealed an 
increase in the prevalence of MS related to age, body mass index, and abdominal 
perimeter. This study also demonstrated the association between metabolic risk fac-
tors, including MS and the occurrence of cardiac events, stroke, and DM [34]. The 
prevalence of MS exhibited a regional variation, being more prevalent in Alentejo 
(30.99%), Madeira (29.38%), Central Region (28.79%), and North Region (28.17%) 
and less prevalent in Algarve (24.42%), Lisbon and Tagus Valley (25.71%), and 
Azores (26.05%) [34].
3. Insulin resistance and metabolic syndrome
The pathophysiology of MS is not yet fully understood, but the most accepted 
hypothesis is insulin resistance, so MS is also known as insulin resistance syn-
drome. Insulin resistance is defined as a defect in its action at the peripheral level 
that results in hyperinsulinemia, required to maintain normal blood glucose [36, 
37]. Predisposing factors for insulin resistance are central obesity and the release 
of large concentrations of free fatty acids from adipose tissue. Free fatty acids in 
the liver will determine the increase in glycogenesis and gluconeogenesis, increased 
triglyceride production, and the secretion of very low-density lipoproteins 
(VLDL).
Insulin is a hormone with anti-lipolytic action that is produced in pancreatic 
beta cells and is released into the bloodstream starting its metabolic effects after 
binding to its receptor. The insulin receptor is a transmembrane glycoprotein 
composed of four subunits linked by disulfide bridges, that is, two extracellular 
alpha subunits that contain the insulin binding domain and two β subunits, which 
contain an extracellular domain, a transmembrane domain, and a intracellular 
domain insulin binding to the α subunit and β subunit, and tyrosine kinase activa-
tion in the β subunit is the first stage of insulin action on glucose metabolism [38, 
39]. The activation of tyrosine kinase, and phosphorylation of the β subunit of the 
insulin receptor, catalyzes the phosphorylation reaction of several tyrosine residues 
in a family of proteins called insulin receptor substrate (IRS), which include IRS-1, 
IRS-2, IRS-3, and IRS-4, which are the most specific in the insulin signaling cas-
cade. Other isoforms are growth factor receptor-bound protein 2 (GRB2)-associated 
binding protein 1 (Gab-1), Shc, and p62 [40, 41].
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Structurally, the four IRS proteins have many similarities, in particular, the phos-
photyrosine-binding domain (PTB), whose function is the recognition sequence 
of asparagine-proline glutamic phosphotyrosine acid (NPEpY) located in the juxta 
membrane region of the β receptor of insulin. It is involved in the interaction of 
IRS proteins with the insulin receptor and with the COOH-terminal domain of the 
proteins, capable of binding to the SH2 domains [39]. In addition to their similari-
ties, the four IRS proteins differ in tissue distribution [39]. The SH2 domain consists 
of 100 amino acids, and it is the phosphotyrosine binding site [41]. The activation of 
proteins that contain the SH2 domain is important for the transmission of the insulin 
signal and thus carry out its functions [39].
The IRS-1 gene located on chromosome 2q36–37 was the first substrate that was 
identified. IRS-1 is involved in many of the actions of insulin, in the activation of 
nitric oxide (NO) synthetase, in the activation of the activity of the iN + pump, and 
in vascular relaxation through activated protein kinases by mitogens (MAP kinase) 
[39, 42].
The IRS-2 gene is found on chromosome 13q34 [43]. The IRS-2 protein and the 
IRS-1 are very similar in structure and functions, and the main difference lies in the 
region between amino acids 591 and 789 of the IRS-2. IRS-2, unlike IRS-1, is more in 
the cellular cytosol [44].
IRS-3 does not appear to be expressed in human cells [39].
IRS-4 is a protein that consists of 1257 amino acids located in the cell membrane 
of various organs in which it is expressed. It was discovered initially in embryonic 
kidney cells. The IRS-4 gene is found on the X chromosome [39].
Insulin causes vascular relaxation through stimulation of NO production in the 
endothelial cells of blood vessels and by reducing the concentration of intracellular 
calcium in muscle and smooth muscle cells by decreasing sensitization of the light 
chains of calcium (Ca2+)-myosin. These effects are mediated by the activation of the 
phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, as 
well as the stimulation of glucose transport in skeletal muscle and vascular adipose 
tissue [45]. In the case of insulin resistance, the increase in lipolysis produces 
greater amounts of fatty acids, promoting greater inhibition of the lipolytic effect 
of insulin, causing an increase in lipolysis [46, 47].
Insulin resistance is defined as the inability of glucose uptake by skeletal muscle 
and adipose tissue and the inability of the liver to inhibit gluconeogenesis in 
response to an increase in insulin [38, 43].
The evidence of the causal relationships between insulin resistance and hyper-
tension is increasing [48]. There are still many uncertainties about the mechanisms 
that link the two conditions, but in addition to the common genetic predisposition 
between insulin resistance and AHT, there are several other possible mechanisms 
that can explain it [48, 49].
The renin-angiotensin-aldosterone system (RAAS) is a therapeutic target 
for AHT. Changes in the RAAS are also important in insulin resistance, and 
the common molecular mechanisms of insulin resistance and AHT are not well 
understood [50, 51].
The RAAS thus plays an important role in MS. Angiotensinogen is a 58 kDa 
protein produced primarily in the liver under physiological conditions, but it can 
be produced in smaller amounts in adipocytes, mesangial cells, and epithelial 
cells of the proximal contoured tubule and in the brain (neurons and glial cells). 
Angiotensinogen by the action of the renin enzyme produced in the glomerular 
juxta cells in the kidney is subjected to cleavage in the amino-terminal acid of 10 
NH2 to form angiotensin I. Angiotensin I is an inactive peptide that is hydroxylated 
by the enzyme angiotensin converter, forming an octapeptide designated angioten-
sin II [50].
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The RAAS has autocrine/paracrine activity in various tissues, especially in the 
skeletal muscle, smooth muscle of blood vessels, kidneys, heart, and pancreas [52]. The 
angiotensin (AT) II receptor is a transmembrane protein that belongs to the family of 
receptors coupled to the G protein which is divided into type I (AT1) and type II (AT2) 
[40, 42, 53]. The genes encoding the AT1 receptor were cloned in 1992, and the genes 
encoding the AT2 receptor were cloned in 1994 [54]. The binding of angiotensin II to 
the AT1 receptor leads to the phosphorylation of various proteins such as IRS-1 and 
IRS-2, making the P110/PI3K subunit the common activation mechanism for the insulin 
signaling pathway. Resistance to insulin is caused by the inhibition of insulin through the 
inhibition of the mechanisms involved in glucose transport and vasodilation [42, 45].
Skeletal muscle is important in the development of insulin resistance, which is 
responsible for 75–95% glucose metabolism [55, 56]. Skeletal muscle constitutes the 
largest insulin-sensitive tissue in the body and is the primary site for insulin-stim-
ulated glucose utilization [55]. Skeletal muscle resistance to insulin is fundamental 
to the metabolic dysregulation associated with obesity and physical inactivity and 
contributes to the development of the MS [55]. Potential mechanisms contributing 
to reduced insulin signaling and action in skeletal muscle include adipose tissue 
expansion and increased inflammatory adipokines, increased RAAS activity, 
decreases in muscle mitochondrial oxidative capacity, increased intramuscular lipid 
accumulation, and increased reactive oxygen species (ROS) [55].
Angiotensin II has prooxidant and pro-inflammatory effects that regulate apopto-
sis, inflammation, cell growth, fibrosis, and insulin sensitivity by inducing the 
formation of oxygen free radicals through the enzyme nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase [56]. ROS are formed by the electron transport 
chain in the mitochondria, and it increases in situations that require the oxidation 
of substrates such as glucose [56]. Multiple ROS activate transcription factors such 
as factor nuclear kappa B (NF-KB) protein-1 and hypoxia-inducible factor-1 HIF-1, 
which are involved in the mechanism of insulin resistance in skeletal muscle [57].
Hyperinsulinemia can alter some of the components of the RAAS such as pro-
fibrotic stimulants and pro-inflammatory actions mediated by angiotensin II and 
can cause cardiovascular disease development [50].
3.1 Relationship between inflammation and insulin resistance
Obesity is a worldwide epidemic that has generated many scientific publications 
in recent years. Thus, new paradigms were emerging, while the old challenges are still 
to be unraveled [58]. Obesity is a chronic disease and has become a major problem 
in most industrialized countries due to its increased prevalence and association with 
various diseases and due to its great economic impact [59]. To preserve the energy 
reserves of body fat during periods of negative energy balance, the body has devel-
oped various regulatory mechanisms [60]. This control is achieved by balancing 
the intestinal absorption of glucose, the production of glucose by the liver, and the 
absorption and metabolism of glucose by peripheral tissues [61]. Insulin regulates 
blood glucose due to its action in stimulating glucose uptake in the muscle and liver 
and inhibiting hepatic gluconeogenesis [61]. Despite the change in tolerance to the 
action of insulin initially, blood glucose is normal because pancreatic β cells have 
the ability to increase the ability of insulin secretion to overcome existing insulin 
resistance [9]. Excess nutrients induce hypertrophy of adipocytes that promote the 
development of various chronic morbidities such as type 2 DM and insulin resistance, 
glucose intolerance, and dyslipidemia with the consequent development of cardiovas-
cular diseases [60]. There is also strong evidence to suggest that cell hypoxia may be an 
important factor in the pathophysiology of adipocytes and may be one of the causes of 
this dysfunction contributing to the metabolic alteration associated with obesity [62].
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Obesity is defined according to the WHO, as an abnormal or excessive accumu-
lation of fat that can cause imbalances in the health of an individual [63]. Males are 
more likely to accumulate intra-abdominal adipose tissue compared with females 
[32, 64]. On average, men have twice the amount of visceral fat than women and 
have a higher prevalence of metabolic diseases associated with obesity and MS [65].
Obesity is associated with a higher incidence of type 2 DM, insulin resistance, 
AHT, dyslipidemia, some types of cancer, and CVD [66]. Fat tissue is deposited in 
two main compartments, subcutaneous and central or visceral [63]. Based on this, 
obesity can be divided into central and peripheral obesity. Central obesity is charac-
terized by hyperplasia and hypertrophy of adipocytes around the intra-abdominal 
organs and is associated with greater development of MS [65].
Adipocyte hypertrophy is the main consequence of excess nutrient intake, 
promoting the development of insulin resistance and glucose intolerance [63]. 
Triglycerides present in fatty tissue are the body’s largest energy reserve, so adipose 
tissue is a very effective energy storage mechanism that allows survival of living 
beings in times of famine [59].
Recent studies have shown that hypoxia in adipose tissue can play an important 
role in the cellular mechanisms of chronic inflammation, macrophage infiltra-
tion, adiponectin reduction, leptin elevation, adipocyte apoptosis, and reticulum 
endoplasmic and mitochondrial dysfunction in white adipose tissue in obese [67].
Hypoxia inhibits pre-adipocyte differentiation and stimulates the secretion of 
leptin and vascular epithelial growth factor (VEGF) of mature adipocytes [68].
There are several genes that regulate the action of hypoxia, such as HIF-1α 
(hypoxia-inducible factor 1α), vascular endothelial growth factor VEGF, glucose 
transporter-1 (GLUT-1), heme oxygenase-1, and pyruvate dehydrogenase kinase 
1 [67]. It was found that, under conditions of hypoxia in adipose tissue, all genes 
increased their expression except for VEGF messenger ribonucleic acid (mRNA) 
[67].
Adipose tissue is thus divided into white adipose tissue and brown adipose 
tissue, which have different functions. Brown adipose tissue has the function of 
producing heat. The understanding and vision we currently have in white adipose 
tissue have changed significantly in the last 15 years [69]. Currently, white adipose 
tissue is considered, not only as a tissue in which energy is stored in the form of tri-
glycerides but also as the main secretory and endocrine organ of the organism [70]. 
White adipose tissue produces and secretes various proteins. Initially, these proteins 
were designated adipocytokines [71]. Currently, it is universally adopted the name 
of adipokines to the set of proteins synthesized and secreted by adipose tissue, since 
not all proteins are cytokines [71].
In addition to adipokines and fatty acids, adipose tissue produces other lipid 
substances such as steroid hormones, prostaglandins and prostanoids, cholesterol, 
and retinol (cholesterol and retinol are not synthesized by adipocytes but are stored 
and released from them) [71].
In 1994, Friedman and his colleagues discovered leptin, a hormone produced 
by white adipose tissue. Leptin, also called OB protein, is a hormone composed 
of 16 kDa and is produced from a protein with molecular weight of 18 kDa. It is 
cleaved leading to the production of leptin protein. Leptin is expressed in many 
tissues including the white and brown adipose tissue, stomach, placenta, mammary 
gland, ovarian follicles, and others [72]. It is expressed primarily in adipose tissue, 
but it is also expressed in smaller amounts in the brain and in the cerebrospinal 
fluid [70].
Leptin acts both in the central nervous system (hypothalamus) and in the 
peripheral organs. This discovery allowed us to realize that adipose tissue is not only 
a tissue in which energy storage occurs but also an endocrine organ [73].
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White adipose tissue produces various adipokines, many of which are inflam-
matory mediators such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-β, 
and IL-6. The production of inflammatory interleukins increases with obesity and 
is involved in the development of insulin resistance and in the metabolic syndrome 
[62, 74]. Adipokines have various functions, in particular in the energy balance 
(e.g., leptin) on insulin sensitivity and glucose metabolism (e.g., adiponectin), 
inflammation (e.g., TNF-α), immunity (e.g., adipsin), lipid metabolism (e.g., 
cholesterol ester transfer protein), blood pressure control (e.g., angiotensinogen) 
hemostasis (e.g., plasminogen activation inhibitor-1), and angiogenesis (e.g., 
vascular epidermal growth factor) [62, 71].
3.2 Relationship between hypoxia and insulin resistance
Inflammation is an important process in obesity and in type 2 DM, as it 
promotes insulin resistance by inhibiting the function of IRS-1 and IRS-2 in the 
pathway insulin signaling [61, 75].
Obesity is characterized by a state of chronic inflammation with increased 
inflammatory parameters, for example, haptoglobin, IL-6, C-reactive protein 
(CRP), plasminogen activator inhibitor-1 (PAI-1), and TNF-α [69]. Large concen-
trations of cytokines produced by adipose tissue, such as TNF-α, IL-6, and IL-1β, 
and low concentrations of certain adiponectins cause chronic hyperinsulinemia and 
insulin resistance [63].
3.3 Relationship between endothelial dysfunction and insulin resistance
During periods of positive energy balance, there is an increase in white adipose 
tissue in order to be able to store excess triglycerides. Consequently, adipose tissue 
becomes hypoxic due to the decrease in vascularization of the same [62]. The role 
of hypoxia in adipose tissue in obesity and insulin resistance is still unclear [76]. 
Regulatory responses mediated by HIF-1 depend on its degree and duration [76].
HIF-1 is a heterodimeric transcription factor induced by hypoxia and composed 
of two subunits, the α subunit consisting of 120 kDa and the β subunit, consisting of 
91 to 94 kDa [77]. The α subunit (HIF-1α) determines the transcriptional activity 
of HIF-1, and its increase occurs in response to hypoxia. The β (HIF-1β) subunit is 
constitutively expressed and may also be referred to as an aryl hydrocarbon receptor 
nuclear translocator (tRNA) [78]. Under normoxia conditions, HIF-1α is hydroxyl-
ated in proline and asparaginyl residues, catalyzed by the enzyme prolylhydroxylase 
(PHD), which promotes binding to an ubiquitin ligase complex. This process 
leads to proteosomal degradation mediated by HIF-1 [76, 78]. Under conditions of 
hypoxia, hydroxylation and activation of HIF-1 target genes are inhibited [76].
HIF-1α activates fibrosis of adipose tissue, causing an increase in macrophage 
infiltration into adipose tissue that mediates a greater increase in inflammation and 
concomitant sensitivity decrease in insulin [79, 80].
VEGF is a target gene of HIF-1. VEGF promotes angiogenesis, a necessary 
process for the differentiation of adipocytes and the growth of adipose tissue [81].
4. Obesity and metabolic syndrome
The endothelium is a layer of cells that lines the inner surface of the blood vessel 
[82]. Endothelial dysfunction is defined as the interruption of the release of vaso-
dilator factors such as NO and prostacyclin (PGI2) and vasoconstrictor factors such 
as endothelin-1 (ET-1) and angiotensin II [74]. Alterations in vascular endothelial 
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function at the level of adipose tissue can cause insulin resistance [81]. In insulin 
resistance, the release rate of free fatty acids from the adipose tissue, which con-
tribute to diabetic dyslipidemia, increased. HDL-cholesterol decreased, increasing 
low-density lipoprotein (LDL) cholesterol and free fatty acids. This stimulates the 
inflammatory response, causing the adhesion of monocytes and lymphocytes to the 
endothelial cells, and increases the flow of glucose and free fatty acids to the cells, 
causing excessive formation of oxygen free radicals, with an increase in metabolic 
and hemodynamic degradation. There is an increase in free radicals and nitrites 
by intramitochondrial enzymatic oxy-reduction which promotes apoptosis and 
impaired vascular endothelial function [82]. This alteration causes insulin meta-
bolic dysfunction, promoting greater resistance to insulin [74, 82].
4.1 Relationship between insulin resistance and hypertension in obesity
Obesity alone is the cause of AHT in 78% of men and 65% of women [83]. 
Evidence of the causal relationship between insulin resistance and AHT is increas-
ing [40]. Under physiological circumstances, insulin and insulin growth factor-1 
(IGF-1) increase vasodilation by stimulating the production of NO and reducing 
the concentration of intravascular calcium in vascular smooth muscle cells. It also 
increases the sensitization of myosin-Ca2+ light chains. These actions are mediated 
through the activation of the PI3K enzyme and the Akt protein. Vascular relaxation 
in response to activation of PI3K/Akt pathway is mediated by endothelial cells 
producing NO, which involves phosphorylation of endothelial NO synthetase [41].
Patients with AHT have an increase in fasting and postprandial insulin levels in 
relation to non-hypertensive patients with the same body mass index [41]. It does 
not occur with secondary AHT but with essential AHT. This is related in part to the 
action of insulin that changes at the level of muscle tissue, which is the predominant 
site of glucose use stimulated by insulin [40].
There is an association between blood pressure and the proportion of type II 
fibers in skeletal muscle, which are less sensitive to insulin than type I fibers [40]. 
Under normal physiological conditions, there is a relationship between glucose-
mediated insulin availability and increased blood flow in response to insulin. 
This response decreases in obese people with insulin resistance, which suggests 
resistance to insulin action in reference to vascular NO production [41]. Due to the 
difficulty of assimilating the rapid growth of adipose tissue in a hypoxia at an early 
stage, conditions are created for an increase in the expression of HIF-1α [84–87].
There is evidence that insulin resistance and hyperinsulinemia predispose 
patients to the development of AHT due to cellular abnormalities in insulin signal-
ing pathways and are associated with metabolic and hemodynamic alterations [84]. 
Metabolic abnormalities are linked to hypertension caused by pathophysiological 
processes that involve the sympathetic-adrenergic system, the imbalance of cell 
cations, the increase in inflammation, the oxidative stress, and the RAAS [40].
RAAS plays an important role in insulin resistance by being more active in 
visceral adipose tissue compared to peripheral adipose tissue [83]. Insulin resistance 
in obese individuals is also associated, in part, with an antagonism to the action 
of angiotensin II (AT II) [83]. This produces a decrease in NO production with an 
increase in vasoconstriction and a decrease in GLUT-4 in skeletal muscle. It also 
reduces glucose uptake and decreases vasodilation in tissues [83]. Under normal 
conditions, the RAAS system is a mechanism for regulating blood pressure [88]. 
With the increase in the activity of the RAAS, there is a greater production of ATII, 
which leads to stimulation of the sympathetic nervous system, insulin resistance, 
sodium retention, and increased intravascular volume. It also contributes to kidney 
disease, hypertension, insulin resistance, and left ventricular hypertrophy [83].
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There is a common genetic predisposition to insulin resistance and hyperten-
sion. Genetic defects have been described in people who had insulin resistance and 
AHT and mutations found on chromosome 7q, where other genes important for 
glycemic control, blood pressure, and obesity are also found [49].
Hyperinsulinemia can directly stimulate the reabsorption of sodium and 
water in the kidney, which increases the volume in the extracellular space, causing 
AHT. Another mechanism by which insulin can cause hypertension involves stimu-
lation of the sympathetic nervous system (SNS) by increasing the concentration of 
norepinephrine. This increase is directly related to the increase in pulse and blood 
pressure by direct effect on the reabsorption of sodium in the kidney, peripheral 
vasoconstriction, and increased cardiac output [9].
5. Conclusion
The correlation of CVRF with the metabolic syndrome differs from one another. 
The notion that CVRF has a tendency to aggregation allows an earlier diagnosis of 
MS, thus also leading to the early introduction of therapeutic, pharmacological, 
or non-pharmacological measures. The prevalence of MS increases with age and 
is present in people of working age, increasing the risk of cardiovascular diseases, 
work-related absences, and socioeconomic costs. The concept of MS was carried 
out in a progressive manner. Its clinical importance is enormous due to the fact that 
it can identify patients with high risk of suffering some CVD and/or DM, allowing 
a preventive intervention. This may explain the importance of understanding the 
pathophysiology of the MS, and the author hopes that at the end of the chapter, the 
reader can understand it. This chapter is the beginning of an explanation of meta-
bolic syndrome that should be complemented by reading other articles.
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